Sign inSubscribe

Search Site

VideosInforgraphics
Sign inSubscribe

Business, Health

DAE net profit up 36.2%

Revenues grew by 9 percent to $1.42bn from $1.31bn in 2023.

Borouge 2024 net profit $1.24bn

The company said it will maintain a $1.3bn dividend for 2025.

ADQ, Orion to establish JV

The partners commit to deploying $1.2bn in the next four years.

Alpha Dhabi acquires interest in NCTH

The deal increases NCTH's portfolio to 8 hotels with 1,500 keys.

Meraas awards construction contract

The $272m contract has been awarded for Bluewaters Bay.

Vaccine factory to come up in Khazaen City with $52m outlay

The rise in producer price index was driven by a hike in oil and gas prices.
By TRENDS Desk
April 9, 2022 12:34 pm
  • The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi
  • Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City

The Khazaen Economic City in Oman has signed an agreement with biopharmaceuticals business company Opal to establish a factory for the production of biological human vaccines, official sources have said.

The deal was signed in Muscat on Wednesday, and has an outlay of OMR20 million (around $52 million), said the sources.

The first phase of the project is expected to be set up on a total area of 37,000 square meters.

The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi.

Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City.

He added that it targets local and international markets.

The agreement, Al Thuhli added, comes as part of Khazaen’s efforts in attracting local and international investments.

Most Read